Abstract
Almost 40 years after the discovery of HIV-1/AIDS, combination anti-retroviral therapy (cART) has dramatically improved the prognosis of people living with HIV (PLWH), and AIDS has become a treatable chronic infection from a fatal disease. Recently, new effective and safe anti-HIV drugs have been developed one after another, and UNAIDS aims to end the AIDS epidemic by 2030. On the other hand, although cART can reduce the viral production in the PLWH’s body below the detection limit, it can not eliminate the HIV provirus integrated into the gene in the host cells. Therefore, the virus will be produced again after discontinuation of the drug. Under such circumstances, research for the cure (or remission) of HIV has been widely carried out. In this review, we focus on the drug development targeting HIV latently infected cells and overview the progress including our current studies.
